Abstract
Background: The human papillomavirus (HPV) has been studied for over a century. Although human warts have been described since ancient times, the presence of HPV in this type of skin and genital lesions was only recognized in the mid-20th century. Currently, HPV is recognized as the most common sexually transmitted infection worldwide. More than 200 genotypes have been identified, with high-risk types being strongly associated with anogenital and oropharyngeal cancers. New therapeutic vaccines currently under study aim to treat established HPV infections in patients with neoplastic lesions at various stages of development. Methods: This study is a descriptive, qualitative, and retrospective study. It was conducted through a systematic bibliographic review of the scientific literature on human papillomavirus (HPV), therapeutic vaccines, and vaccination strategies. Results: Although no therapeutic vaccine has yet been approved for use in humans, preliminary results are encouraging and suggest a potential impact in reducing the progression to invasive cancer. Based on the results obtained by the authors included in this review, we can conclude that therapeutic vaccines are emerging not only as a medical necessity, but as one of the most promising tools in the evolution of treatment for HPV and its related pathologies. Conclusión: Therapeutic vaccines have the potential to become a central pillar of clinical management for high-grade intraepithelial lesions (CIN 2/3) and early cervical cancer, as they not only provide a less invasive strategy than traditional surgical treatments but could also help reduce disease recurrence and improve patients' quality of life.
References
1. Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. Global and regional estimates of human papillomavirus (HPV) prevalence in women: a pooled analysis of 1 million women from 194 studies in the HPV Information Centre. Lancet Glob Health. 2023;11(3):e223–e234. https://doi.org/10.1016/S2214-109X(22)00477-2
2. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17. https://doi.org/10.1128/CMR.16.1.1-17.2003
3. Drolet M, Bénard É, Pérez N, Brisson M, HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509. https://doi.org/10.1016/S0140-6736(19)30298-3
4. Ghittoni R, Accardi R, Chiocca S, Tommasino M. Role of human papillomaviruses in carcinogenesis. Ecancermedicalscience. 2015;9:526. https://doi.org/10.3332/ecancer.2015.526
5. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study. Lancet. 2009;374(9686):301–314. https://doi.org/10.1016/S0140-6736(09)61248-4
6. Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086. https://doi.org/10.1038/nrdp.2016.86
7. Shope RE, Hurst EW. Infectious papillomatosis of rabbits: with a note on the histopathology. J Exp Med. 1933;58(5):607–624. https://doi.org/10.1084/jem.58.5.607
8. Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting HPV 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomized, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–2088. https://doi.org/10.1016/S0140-6736(15)00246-6
9. van Poelgeest MIE, Welters MJP, Vermeij R, et al. Vaccination against oncogenic human papillomavirus types with E6 and E7 long peptides in vulvar intraepithelial neoplasia. N Engl J Med. 2015;372(15):1345–1356. https://doi.org/10.1056/NEJMoa1405362
10. World Health Organization. WHO preferred product characteristics for therapeutic HPV vaccines. 2023. https://www.who.int/publications/i/item/9789240092174
11. Zur Hausen H. Papillomaviruses in the causation of human cancers—a brief historical account. Virology. 2009;384(2):260–265. https://doi.org/10.1016/j.virol.2008.11.046
12. Arroyo Mühr LS, Gini A, Yilmaz E, Hassan SS, Lagheden C, Hultin E, et al. Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer. Nat Commun 2024;15:3679. https://doi.org/10.1038/s41467-024-47909-x.
13. Conageski C. Human Papillomavirus Vaccines. Clin Obstet Gynecol 2023;66:433–47. https://doi.org/10.1097/GRF.0000000000000788.
14. Gong X, Chi H, Xia Z, Yang G, Tian G. Advances in HPV-associated tumor management: Therapeutic strategies and emerging insights. J Med Virol 2023;95:e28950. https://doi.org/10.1002/jmv.28950.
15. Han F, Guo X-Y, Jiang M-X, Xia N-S, Gu Y, Li S-W. Structural biology of the human papillomavirus. Structure 2024;32:1877–92. https://doi.org/10.1016/j.str.2024.09.011.
16. Harper DM, Navarro-Alonso JA, Bosch FX, Paavonen J, Stanley M, Sasieni P, et al. Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review. Hum Vaccin Immunother 2025;21:2497608. https://doi.org/10.1080/21645515.2025.2497608.
17. Hernández-Silva CD, Ramírez de Arellano A, Pereira-Suárez AL, Ramírez-López IG. HPV and Cervical Cancer: Molecular and Immunological Aspects, Epidemiology and Effect of Vaccination in Latin American Women. Viruses 2024;16:327. https://doi.org/10.3390/v16030327.
18. Kim M, Kim E. Effective vaccination strategies for human papillomavirus (HPV) infection and cervical cancer based on the mathematical model with a stochastic process. J Med Virol 2024;96:e29558. https://doi.org/10.1002/jmv.29558.
19. Li Y, Zhao F, Wu D, Qin C, Lu Y, Yang Y, et al. Prevalence of Human Papillomavirus and Genotype Distribution in Chinese Men: A Systematic Review and Meta-Analysis. Cancer Med 2025;14:e70686. https://doi.org/10.1002/cam4.70686.
20. Liu Y, Ai H. Comprehensive insights into human papillomavirus and cervical cancer: Pathophysiology, screening, and vaccination strategies. Biochim Biophys Acta Rev Cancer 2024;1879:189192. https://doi.org/10.1016/j.bbcan.2024.189192.
21. Marfo EA, King KD, Adjei CA, MacDonald SE. Features of human papillomavirus vaccination education strategies in low- and middle-income countries: a scoping review. Public Health 2022;213:61–7. https://doi.org/10.1016/j.puhe.2022.09.013.
22. Oyouni AAA. Human papillomavirus in cancer: Infection, disease transmission, and progress in vaccines. J Infect Public Health 2023;16:626–31. https://doi.org/10.1016/j.jiph.2023.02.014.
23. Peng S, Ferrall L, Gaillard S, Wang C, Chi W-Y, Huang C-H, et al. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody. mBio 2021;12:e03224-20. https://doi.org/10.1128/mBio.03224-20.
24. Plotzker RE, Vaidya A, Pokharel U, Stier EA. Sexually Transmitted Human Papillomavirus: Update in Epidemiology, Prevention, and Management. Infect Dis Clin North Am 2023;37:289–310. https://doi.org/10.1016/j.idc.2023.02.008.
25. Rahangdale L, Mungo C, O’Connor S, Chibwesha CJ, Brewer NT. Human papillomavirus vaccination and cervical cancer risk. BMJ 2022;379:e070115. https://doi.org/10.1136/bmj-2022-070115.
26. Setiawan D, Nurulita NA, Khoirunnisa SM, Postma MJ. The clinical effectiveness of one-dose vaccination with an HPV vaccine: A meta-analysis of 902,368 vaccinated women. PLoS One 2024;19:e0290808. https://doi.org/10.1371/journal.pone.0290808.
27. Shapiro GK. HPV Vaccination: An Underused Strategy for the Prevention of Cancer. Curr Oncol 2022;29:3780–92. https://doi.org/10.3390/curroncol29050303.
28. Skolnik JM, Morrow MP. Vaccines for HPV-associated diseases. Mol Aspects Med 2023;94:101224. https://doi.org/10.1016/j.mam.2023.101224.
29. Wirtz C, Mohamed Y, Engel D, Sidibe A, Holloway M, Bloem P, et al. Integrating HPV vaccination programs with enhanced cervical cancer screening and treatment, a systematic review. Vaccine 2022;40 Suppl 1:A116–23. https://doi.org/10.1016/j.vaccine.2021.11.013.
30. Włoszek E, Krupa K, Skrok E, Budzik MP, Deptała A, Badowska-Kozakiewicz A. HPV and Cervical Cancer-Biology, Prevention, and Treatment Updates. Curr Oncol 2025;32:122. https://doi.org/10.3390/curroncol32030122.
31. Yousefi Z, Aria H, Ghaedrahmati F, Bakhtiari T, Azizi M, Bastan R, et al. An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy. Front Immunol 2021;12:805695. https://doi.org/10.3389/fimmu.2021.805695.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Tomás Agustín Barcasia, Susana Irma Carnovale (Author)